Loading
A phase 1 trial of CLN-049 run by Cullinan Therapeutics Inc., not yet recruiting.
A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients is a phase 1 interventional study registered as NCT07722767 by Cullinan Therapeutics Inc., with 90 participants planned, started 2026-10-15. Conditions recorded: AML (Acute Myeloid Leukemia). Interventions recorded: CLN-049, Azacitidine and Venetoclax.
Shares CLN-049, Cullinan Therapeutics, Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/